Open access · CC-BY
via OpenAlex
Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis
Wenbin Liu, Yang Deng, Zishuai Li, Yifan Chen, Xiaoqiong Zhu, Xiaojie Tan, Guangwen Cao
Frontiers in Immunology · 2021 · ▲ 69 citations
Telomere attrition
Cellular senescence
Altered intercellular communication
Chronic inflammation
Exercise
Abstract
Chronic inflammation is a prerequisite for the development of cancers. Here, we present the framework of a novel theory termed as Cancer Evolution-Development (Cancer Evo-Dev) based on the current understanding of inflammation-related carcinogenesis, especially hepatocarcinogenesis induced by chronic infection with hepatitis B virus. The interaction between genetic predispositions and environmental exposures, such as viral infection, maintains chronic non-resolving inflammation. Pollution, metabolic syndrome, physical inactivity, ageing, and adverse psychosocial exposure also increase the risk of cancer via inducing chronic low-grade smoldering inflammation. Under the microenvironment of non-resolving inflammation, pro-inflammatory factors facilitate the generation of somatic mutations and viral mutations by inducing the imbalance between the mutagenic forces such as cytidine deaminases and mutation-correcting forces including uracil–DNA glycosylase. Most cells with somatic mutations and mutated viruses are eliminated in survival competition. Only a small percentage of mutated cells survive, adapt to the hostile environment, retro-differentiate, and function as cancer-initiating cells via altering signaling pathways. These cancer-initiating cells acquire stem-ness, reprogram metabolic patterns, and affect the microenvironment. The carcinogenic process follows the law of “mutation-selection-adaptation”. Chronic physical activity reduces the levels of inflammation via upregulating the activity and numbers of NK cells and lymphocytes and lengthening leukocyte telomere(definition); downregulating proinflammatory cytokines including interleukin-6 and senescent lymphocytes especially in aged population. Anti-inflammation medication reduces the occurrence and recurrence of cancers. Targeting cancer stemness signaling pathways might lead to cancer eradication. Cancer Evo-Dev not only helps understand the mechanisms by which inflammation promotes the development of cancers, but also lays the foundation for effective prophylaxis and targeted therapy of various cancers.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fimmu.2021.768098
- Canonical
- link ↗
- Fetched
- 2026-09-04 MST
Cite this
APA
Liu, W., Deng, Y., Li, Z., Chen, Y., Zhu, X., Tan, X., & Cao, G. (2021). Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis. <em>Frontiers in Immunology</em>. https://doi.org/10.3389/fimmu.2021.768098
Vancouver
Liu W, Deng Y, Li Z, Chen Y, Zhu X, Tan X, et al. Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis. Frontiers in Immunology. 2021. doi:10.3389/fimmu.2021.768098.
BibTeX
@article{wenbin2021Cancer,
title = {Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis},
author = {Wenbin Liu and Yang Deng and Zishuai Li and Yifan Chen and Xiaoqiong Zhu and Xiaojie Tan and Guangwen Cao},
journal = {Frontiers in Immunology},
year = {2021},
doi = {10.3389/fimmu.2021.768098},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical Interventions in Aging 2019
Open access · CC-BY
Could Inflammaging and Its Sequelae Be Prevented or Mitigated?
Trends in cancer 2020
Open access · CC-BY
Senescent Cells in Cancer Therapy: Friends or Foes?
Annals of the Rheumatic Diseases 2015
Open access · CC-BY
Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome
PubMed 2010
Preprint · OA
Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis.
Cellular and Molecular Life Sciences 2016
Open access · CC-BY
Reactivation of telomerase in cancer
Frontiers in Oncology 2020
Open access · CC-BY